Expert Interview
A Second Look: Digging into the Alzheimer's Landscape with a focus on Lilly's recent TRAILBLAZER-ALZ 2 Phase 3 study compared to Biogen's Leqembi
Ticker(s): LLY, BIIBInstitution: Stanford University
- Neurologist at Stanford with a focus on behavorial neurology.
- Currently manages over 300 patients with Alzheimer's Disease.
- Investigator on the CLARITY AD trial (lecanemab), the EMBARK and ENVISION studies (aducanumab), and the LEADS, AHEAD3-45, and AUTONOMY trials.
On a scale of 1 to 10, how would you rate each of the drugs?
Added By: max_adminHow does each drug differ in its mechanism of action?
Added By: max_adminUnder what circumstances would you prescribe one drug over another?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
